Lung Cancer in Estonia
- PMID: 39112000
- DOI: 10.1016/j.jtho.2024.04.017
Lung Cancer in Estonia
Conflict of interest statement
Disclosure Dr. T. Laisaar reports receiving grants from Roche Estonia and Estonian Health Insurance Fund; and funding support from AstraZeneca. Prof. Jaal reports receiving consulting fees from AstraZeneca; honoraria for lectures from AstraZeneca, Pfizer, and Roche; support for travels and meeting from MSD and AstraZeneca; and is a board member of the Estonian Society of Clinical Oncologists. Dr. Oselin reports receiving research grants from Optellum and Pfizer; consulting fees from MSD, Roche, Johnson & Johnson, Amgen, Takeda, and Servier; honoraria for MSD; and support for attending international conferences from MSD, Roche, and Astra Zeneca. Dr. Innos reports receiving institutional grant from the Estonian Research Council (grant no PRG722). Dr. K-T. Laisaar reports receiving grant funding from the European Commission and Estonian Health Insurance Fund, payment for expert testimony from the Estonian Health Insurance Fund; and is a member of the Steering Group Committee at the Estonian Ministry of Social Affairs. The remaining authors declare no conflict of interest.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
